Vaccine Therapy in Treating Patients With Stage I or Stage II Pancreatic Cancer
|ClinicalTrials.gov Identifier: NCT00003025|
Recruitment Status : Completed
First Posted : August 12, 2004
Last Update Posted : July 3, 2013
RATIONALE: Vaccines made from a person's cancer cells may make the body build an immune response to and kill tumor cells. Combining vaccine therapy with surgery may be an effective treatment for pancreatic cancer.
PURPOSE: Phase I trial to study the effectiveness of vaccine therapy in treating patients with stage I or stage II pancreatic cancer that has been surgically removed.
|Condition or disease||Intervention/treatment||Phase|
|Pancreatic Cancer||Biological: vitespen||Phase 1|
OBJECTIVES: I. Study the safety of autologous tumor derived gp96 heat shock protein peptide complex (HSPPC-96) in patients with resected pancreatic adenocarcinoma. II. Examine the immune response to HSPPC-96 in this group of patients.
OUTLINE: This is a dose escalation study. Six weeks after surgery patients are given autologous tumor derived gp96 heat shock protein peptide complex (HSPPC-96) subcutaneously once a week for 4 weeks. Five patients are initially enrolled at each of two dose levels. An additional three patients may be enrolled at each dose level to determine the optimal dose of HSPPC-96. Patients are followed at weeks 1, 4, and 12 after treatment.
PROJECTED ACCRUAL: A maximum of 16 patients will be accrued for this study.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||16 participants|
|Official Title:||A Phase I Pilot Trial of Immunotherapy With Autologous Tumor-Derived gp96 Heat Shock Protein - Peptide Complex (HSPPC-96) in Patients With Resected Pancreatic Adenocarcinoma|
|Study Start Date :||March 1997|
|Primary Completion Date :||July 2002|
|Study Completion Date :||July 2002|
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00003025
|United States, New York|
|Memorial Sloan-Kettering Cancer Center|
|New York, New York, United States, 10021|
|Study Chair:||Jonathan Lewis, MD, PhD, FACS||Memorial Sloan Kettering Cancer Center|